INTERLEUKIN 6

Open Access
Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Kazuhiko Yamamoto, Hajime Goto, Kenzo Hirao, Atsuo Nakajima, Hideki Origasa, Kunihiko Tanaka, Minako Tomobe and Kyoichi Totsuka

The Journal of Rheumatology August 1 2015, 42 (8) 1368-1375; DOI: https://doi.org/10.3899/jrheum.141210
You have access
Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center
Enrico Tombetti, Stefano Franchini, Maurizio Papa, Maria Grazia Sabbadini and Elena Baldissera

The Journal of Rheumatology December 1 2013, 40 (12) 2047-2051; DOI: https://doi.org/10.3899/jrheum.130536
You have access
Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis
Keiko Shimamoto, Tomoki Ito, Yoshio Ozaki, Hideki Amuro, Akihiro Tanaka, Tohru Nishizawa, Yonsu Son, Muneo Inaba and Shosaku Nomura

The Journal of Rheumatology July 1 2013, 40 (7) 1074-1081; DOI: https://doi.org/10.3899/jrheum.121389
You have access
Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
Angelo De Lauretis, Piersante Sestini, Panagiotis Pantelidis, Rachel Hoyles, David M. Hansell, Nicole S.L. Goh, Christopher J. Zappala, Dina Visca, Toby M. Maher, Christopher P. Denton, Voon H. Ong, David J. Abraham, Peter Kelleher, Laureen Hector, Athol U. Wells and Elisabetta A. Renzoni

The Journal of Rheumatology April 1 2013, 40 (4) 435-446; DOI: https://doi.org/10.3899/jrheum.120725

Main menu

User menu

Search

INTERLEUKIN 6

Content

Resources

Subscribers

More